These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28541026)

  • 21. Alpha-lipoic acid in the treatment of autonomic diabetic neuropathy (controlled, randomized, open-label study).
    Tankova T; Koev D; Dakovska L
    Rom J Intern Med; 2004; 42(2):457-64. PubMed ID: 15529636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha-lipoic acid in the treatment of diabetic polyneuropathy in Germany: current evidence from clinical trials.
    Ziegler D; Reljanovic M; Mehnert H; Gries FA
    Exp Clin Endocrinol Diabetes; 1999; 107(7):421-30. PubMed ID: 10595592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis.
    Ziegler D; Nowak H; Kempler P; Vargha P; Low PA
    Diabet Med; 2004 Feb; 21(2):114-21. PubMed ID: 14984445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of 3-month treatment with the antioxidant alpha-lipoic acid in diabetic peripheral neuropathy.
    Negrişanu G; Roşu M; Bolte B; Lefter D; Dabelea D
    Rom J Intern Med; 1999; 37(3):297-306. PubMed ID: 15532308
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of α-lipoic acid in diabetic neuropathy.
    Papanas N; Ziegler D
    Expert Opin Pharmacother; 2014 Dec; 15(18):2721-31. PubMed ID: 25381809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Burning through the pain: treatments for diabetic neuropathy.
    Javed S; Alam U; Malik RA
    Diabetes Obes Metab; 2015 Dec; 17(12):1115-25. PubMed ID: 26179288
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacological significance of alpha lipoic acid in up to date treatment of diabetic neuropathy].
    Becić F; Kapić E; Rakanović-Todić M
    Med Arh; 2008; 62(1):45-8. PubMed ID: 18543755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain.
    Irving G; Tanenberg RJ; Raskin J; Risser RC; Malcolm S
    Int J Clin Pract; 2014 Sep; 68(9):1130-40. PubMed ID: 24837444
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy of morphine, pregabalin, gabapentin, and duloxetine on mechanical allodynia is different from that on neuroma pain in the rat neuropathic pain model.
    Miyazaki R; Yamamoto T
    Anesth Analg; 2012 Jul; 115(1):182-8. PubMed ID: 22415534
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy.
    Ko SH; Kwon HS; Yu JM; Baik SH; Park IB; Lee JH; Ko KS; Noh JH; Kim DS; Kim CH; Mok JO; Park TS; Son HS; Cha BY
    Diabet Med; 2010 Sep; 27(9):1033-40. PubMed ID: 20722677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination therapy in treatment of peripheral diabetic neuropathy with severe pain in an adolescent patient.
    Eyigor C; Uyar M; Pirildar S; Coker M
    Paediatr Anaesth; 2009 Feb; 19(2):193-4. PubMed ID: 19207920
    [No Abstract]   [Full Text] [Related]  

  • 32. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.
    Hanna M; O'Brien C; Wilson MC
    Eur J Pain; 2008 Aug; 12(6):804-13. PubMed ID: 18262450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The effect of long-chain polyunsaturated higher ω-3 fatty acids, benfotiamine and α-lipoic acid on the lipid metabolism in patients with diabetes mellitus type 2 and cardiovascular autonomic neuropathy].
    Sergienko VA; Segin VB; Samir A; Sergienko AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(11):54-8. PubMed ID: 24429949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. α-Lipoic acid, diabetic neuropathy, and Nathan's prophecy.
    Papanas N; Maltezos E
    Angiology; 2012 Feb; 63(2):81-3. PubMed ID: 22253286
    [TBL] [Abstract][Full Text] [Related]  

  • 35. From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy.
    Ziegler D; Fonseca V
    J Diabetes Complications; 2015; 29(1):146-56. PubMed ID: 25239450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Pharmacologic therapy in peripheral diabetic polyneuropathy].
    Mihai B; Lăcătuşu C; Graur M; Cijevschi-Prelipcean C; Mihai C
    Rev Med Chir Soc Med Nat Iasi; 2010; 114(2):332-41. PubMed ID: 20700963
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alpha-Lipoic Acid for Treatment of Diabetic Peripheral Neuropathy.
    Bartkoski S; Day M
    Am Fam Physician; 2016 May; 93(9):786. PubMed ID: 27175957
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy.
    Foster TS
    Diabetes Educ; 2007; 33(1):111-7. PubMed ID: 17272797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy.
    Bellows BK; Dahal A; Jiao T; Biskupiak J
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):153-64. PubMed ID: 22509775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of alpha-lipoic acid on symptoms and skin blood flow in diabetic neuropathy.
    Jin HY; Joung SJ; Park JH; Baek HS; Park TS
    Diabet Med; 2007 Sep; 24(9):1034-8. PubMed ID: 17490418
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.